Memorial Sloan Kettering physicians and scientists are pioneering the development of targeted therapies for kidney cancer. In fact, our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.
Medical oncologist Robert Motzer and physician-scientist James Hsieh explain how patients can benefit dramatically from these drugs. Our experts, including clinical research nurses Patricia Fischer and Suzanne Gornell, personalize the care of each patient. Our patients receive many of these treatments through clinical trials led by Memorial Sloan Kettering investigators.
Meet two patients who share their experiences of receiving targeted kidney cancer therapies at Memorial Sloan Kettering. Our experts are continuing to lead the development and refinement of targeted therapies for kidney cancer through laboratory research and clinical trials, so patients around the world can benefit.